ArticleBritish journal of haematology2022

The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.

Natsumi Kawasaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.